Sumary of Pfizer’s COVID-19 vaccine prevents 90% of infections in large study:
- Eight months into the worst pandemic in a century, the preliminary results pave the way for the companies to seek an emergency-use authorization from regulators if further research shows the shot is also safe..
- If the data hold up and a key safety readout Pfizer expects in about a week also looks good, it could mean that the world has a vital new tool to control a pandemic that has killed more than 1.2 million people worldwide..
- However, the strong reading from the first large-scale trial to post efficacy results bodes well for other experimental vaccines, in particular one being developed by Moderna Inc..
- So far, the trial data monitoring committee has identified no serious safety concerns, Pfizer and BioNTech said..
- Pfizer had originally planned to conduct a first analysis of trial data after just 32 virus cases had occurred in the trial, which has enrolled 43,538 volunteers in multiple countries..
- regulators, Pfizer and BioNTech said they recently elected to drop the 32-case analysis and conduct the first analysis at a minimum of 62 cases, one of several changes made in the trial-analysis plan..
- While Pfizer conducted those negotiations, it paused testing of participant samples for the virus, said Gruber..
- By the time Pfizer had made the changes in the trial plan and restarted virus testing a few days ago, some 94 cases had occurred, far more than the trial needed to meet the new threshold…